\
&
Contact us
\
&
Contact us
Published on | 6 months ago
Programmes MSCA Research Infrastructures Health Culture and society Security Digital, Industry & Space Climate, Energy, Mobility Agro-Food, Environment EIE Widening/Spreading Missions New European Bauhaus Horizon EuropeThe programme committee configurations gave a positive opinion on the work programme 2025. Thus, the draft texts of the Horizon Europe ‘main’ work programme 2025 and the amendment of the Horizon Europe ‘main’ work programme 2023-2025 have been pre-published. They are available on the Commission's Horizon Europe work programmes webpage.
The adoption of the work programme and opening of first calls for proposals are planned by mid-May.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Security Digital, Industry & Space Cybersecurity
The European Commission has opened a call for evidence to shape the future EU Quantum Act, expected to be adopted in 2026. This initiative aims to enhance research, industrial capacity, and supply chain resilience in quantum technologies. The call for contributions is open to a wide range of stakeholders, including Member State authorities, EU age... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
